{"id":210039,"name":"ABPRO CORPORATION","slug":"abpro-corporation","state":"MA","country":"United States of America","description":"Biotechnology company developing next generation antibody therapeutics.","totalSpending":150000,"filings":12,"yearlySpending":[{"year":2021,"income":90000},{"year":2022,"income":60000},{"year":2023,"income":0}],"issues":[{"code":"DIS","display":"Disaster Planning/Emergencies"},{"code":"HCR","display":"Health Issues"}],"firms":["K&L GATES, LLP"],"lobbyists":["BRUCE HEIMAN","DENNIS POTTER","AMY CARNEVALE"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE","Natl Institutes of Health (NIH)","White House Office"],"sampleDescriptions":["Advancing U.S. preparedness for treatment of COVID-19 variants with next generation monoclonal antibody therapeutics.","Advancing U.S. preparedness for treatment of COVID-19 variants with next generation monoclonal antibody therapeutics.","Issues related to advancing U.S. preparedness for treatment of COVID-19 variants with next generation monoclonal antibody therapeutics - no specific legislation.","Issues related to advancing U.S. preparedness for treatment of COVID-19 variants with next generation monoclonal antibody therapeutics - no specific legislation.","Issues related to advancing U.S. preparedness for treatment of COVID-19 variants with next generation monoclonal antibody therapeutics - no specific legislation."]}